50 related articles for article (PubMed ID: 17438099)
21. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Chabner BA; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(21):6540. PubMed ID: 17975169
[No Abstract] [Full Text] [Related]
22. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
23. Publication outcomes of phase II oncology clinical trials.
Hoeg RT; Lee JA; Mathiason MA; Rokkones K; Serck SL; Crampton KL; Emmel AE; Severson EA; Go RS
Am J Clin Oncol; 2009 Jun; 32(3):253-7. PubMed ID: 19349853
[TBL] [Abstract][Full Text] [Related]
24. Phase II cancer trials: out of control?
Chabner B
Clin Cancer Res; 2007 Apr; 13(8):2307-8. PubMed ID: 17438086
[No Abstract] [Full Text] [Related]
25. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
Michaelis LC; Ratain MJ
Clin Cancer Res; 2007 Apr; 13(8):2400-5. PubMed ID: 17438099
[TBL] [Abstract][Full Text] [Related]
26. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
27. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
28. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
29. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
30. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
31. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside.
Sakamoto J; Morita S
Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
Ohorodnyk P; Eisenhauer EA; Booth CM
Eur J Cancer; 2009 Sep; 45(13):2249-52. PubMed ID: 19545996
[TBL] [Abstract][Full Text] [Related]
33. Some ethical issues in phase II trials in acute leukemia.
Thall PF; Estey EH
Clin Adv Hematol Oncol; 2005 Dec; 3(12):943-8. PubMed ID: 16555436
[TBL] [Abstract][Full Text] [Related]
34. The quality of reporting of trial abstracts is suboptimal: survey of major general medical journals.
Berwanger O; Ribeiro RA; Finkelsztejn A; Watanabe M; Suzumura EA; Duncan BB; Devereaux PJ; Cook D
J Clin Epidemiol; 2009 Apr; 62(4):387-92. PubMed ID: 19010643
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
36. Considerations in the rational design and conduct of phase I/II pediatric clinical trials: avoiding the problems and pitfalls.
Abdel-Rahman SM; Reed MD; Wells TG; Kearns GL
Clin Pharmacol Ther; 2007 Apr; 81(4):483-94. PubMed ID: 17329988
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review.
Rivoirard R; Langrand-Escure J; Oriol M; Tinquaut F; Chauvin F; Rancoule C; Magné N; Bourmaud A
Crit Rev Oncol Hematol; 2018 May; 125():78-83. PubMed ID: 29650280
[TBL] [Abstract][Full Text] [Related]
38. Uncommon anal neoplasms.
Billingsley KG; Stern LE; Lowy AM; Kahlenberg MS; Thomas CR
Surg Oncol Clin N Am; 2004 Apr; 13(2):375-88. PubMed ID: 15137963
[TBL] [Abstract][Full Text] [Related]
39. [Randomized Phase II Trial Designs in Oncology].
Yoshimura K
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1561-1566. PubMed ID: 30449838
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
